Want to see LUCD full AI Analyst Report?
Total Valuation
Lucid Diagnostics has a market cap or net worth of $195.20M. The enterprise value is $187.45.
Market Cap$195.20M
Enterprise Value$187.45
Share Statistics
Lucid Diagnostics has 203,243,970 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding203,243,970
Owned by Insiders5.36%
Owned by Institutions11.35%
Financial Efficiency
Lucid Diagnostics’s return on equity (ROE) is -5.30 and return on invested capital (ROIC) is -135.05%.
Return on Equity (ROE)-5.30
Return on Assets (ROA)-1.43
Return on Invested Capital (ROIC)-135.05%
Return on Capital Employed (ROCE)-4.18
Revenue Per Employee57.39K
Profits Per Employee-707.44K
Employee Count82
Asset Turnover0.12
Inventory Turnover21.37
Valuation Ratios
The current PE Ratio of Lucid Diagnostics is ―. Lucid Diagnostics’s PEG ratio is 0.05.
PE Ratio―
PS Ratio23.61
PB Ratio10.16
Price to Fair Value10.16
Price to FCF-2.39
Price to Operating Cash Flow-3.77
PEG Ratio0.05
Income Statement
In the last 12 months, Lucid Diagnostics had revenue of 4.71M and earned -58.01M in profits. Earnings per share was -0.69.
Revenue4.71M
Gross Profit-2.84M
Operating Income-49.64M
Pretax Income-58.01M
Net Income-58.01M
EBITDA-57.12M
Earnings Per Share (EPS)-0.69
Cash Flow
In the last 12 months, operating cash flow was -46.87M and capital expenditures -315.00K, giving a free cash flow of -47.18M billion.
Operating Cash Flow-46.87M
Free Cash Flow-47.18M
Free Cash Flow per Share-0.23
Dividends & Yields
Lucid Diagnostics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.34
52-Week Price Change-16.90%
50-Day Moving Average0.99
200-Day Moving Average1.12
Relative Strength Index (RSI)48.12
Average Volume (3m)1.86M
Important Dates
Lucid Diagnostics upcoming earnings date is Nov 16, 2026, After Close (Confirmed).
Last Earnings DateAug 13, 2026
Next Earnings DateNov 16, 2026
Ex-Dividend Date―
Financial Position
Lucid Diagnostics as a current ratio of 1.31, with Debt / Equity ratio of 227.96%
Current Ratio1.31
Quick Ratio1.30
Debt to Market Cap0.22
Net Debt to EBITDA0.16
Interest Coverage Ratio-2.26K
Taxes
In the past 12 months, Lucid Diagnostics has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Lucid Diagnostics EV to EBITDA ratio is -1.79, with an EV/FCF ratio of -2.20.
EV to Sales21.72
EV to EBITDA-1.79
EV to Free Cash Flow-2.20
EV to Operating Cash Flow-2.20
Balance Sheet
Lucid Diagnostics has $33.40M in cash and marketable securities with $24.91M in debt, giving a net cash position of $8.49M billion.
Cash & Marketable Securities$33.40M
Total Debt$24.91M
Net Cash$8.49M
Net Cash Per Share$0.04
Tangible Book Value Per Share$0.10
Margins
Gross margin is -25.79%, with operating margin of -1054.82%, and net profit margin of -1232.68%.
Gross Margin-25.79%
Operating Margin-1054.82%
Pretax Margin-1232.68%
Net Profit Margin-1232.68%
EBITDA Margin-1213.68%
EBIT Margin-1232.21%
Analyst Forecast
The average price target for Lucid Diagnostics is $4.19, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$4.19
Price Target Upside360.16% Upside
Analyst ConsensusStrong Buy
Analyst Count4
Revenue Growth Forecast24.89%
EPS Growth Forecast55.16%